-+ 0.00%
-+ 0.00%
-+ 0.00%
Megaport Holders Are Up 77% And The Case Still Cuts Both Ways
Share
Listen to the news

If Megaport was on your watchlist instead of in your portfolio, the outcome over 2026 may feel like a missed shot. Holding Megaport from the start of the year would have returned 76.6%, including dividends. That move sits against a backdrop of analysts already split between bullish expectations for cloud and AI driven interconnection growth and bearish worries about hyperscalers internalising connectivity. If you were judging this on 1 January, which assumption about who would own future AI and cloud traffic looked more convincing?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

This theme extends beyond Megaport. See which of 91 AI infrastructure stocks may still merit a closer look.

The Two Megaport Stories Investors Had To Weigh

The shares cost A$12.17 at the start, and anyone looking at Megaport then had to choose between two very different but reasonable stories.

On the optimistic side, the bull Narrative set Fair Value at A$15.17, described as 25% above the start price. It leaned on an assumption of 18.2% annual revenue growth and profit margins rising to 6.7%, supported by new data centres, extra services and automation.

The bear Narrative pointed to a Fair Value of A$9, which is 26% below the start price. It focused on risks from stricter data laws that could limit global connectivity and from hyperscalers internalising more networking, which might pressure Megaport’s pricing power and recurring revenue.

ASX:MP1 Trailing 12-Month Earnings & Revenue History as at Oct 2026
ASX:MP1 Trailing 12-Month Earnings & Revenue History as at Oct 2026

What The Megaport Evidence Actually Tested

Megaport’s later move into large AI infrastructure contracts, GPU Pool spending and the A$827.3m capital raise lined up with the bull case that expected cloud and AI demand to widen its opportunity. The reported H2 2026 numbers told a harder story. Revenue reached A$177.3m, yet the firm reported a larger loss and net margin fell to -11.2%. Overall, the evidence cut both ways.

The key assumption here was not just growth, but profitable growth. When you weigh another stock with a similar AI story, check whether higher sales arrive alongside a less negative net margin or a clear path toward positive earnings.

What Megaport's Run Up Leaves You Paying For

Megaport now trades at A$21.01 from the start of the year. The selected Narrative places its Fair Value below that level, reflecting a view that the current quote already prices in ambitious assumptions about scale, profitability and P/E.

A buyer at today’s price is effectively backing strong recurring revenue and high margins to hold. How does the selected Narrative’s regulatory and customer concentration risk challenge that assumption?

"Growing geopolitical tensions and tightening regulatory frameworks, such as more stringent data sovereignty and cross-border data transfer laws, may significantly limit Megaport's ability to offer global connectivity, curbing revenue growth as multinational customers seek more localized, siloed solutions. The continued consolidation among hyperscale cloud providers and large telecoms threatens to reduce the addressable market for independent platforms like Megaport, leading to a potential loss of pricing power and compression of long-term margins as larger players increasingly internalize network connectivity in-house."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Find Your Own Contrarian Opportunity

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

  • Company 1 - 34% below our estimate - scales production after integrating new assets and upgrading key mines and plants.
  • Company 2 - 23% below our estimate - expands pharmacy franchises as prescription demand and higher value health categories reshape store baskets.
  • Company 3 - 36% below our estimate - grows fee streams by adding affiliates and distributing more performance-fee eligible investment products.

Three companies from the same screener. Open all 6 potentially undervalued companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending